Closely held AINGENS is addressing one of healthcare’s most persistent operational challenges—the costly, laborious process of transforming scientific data into compliant, actionable content. The company developed an...
Ascelia Pharma (STO: ACE) has announced that the U.S. Food and Drug Administration (FDA) has scheduled a Type A meeting for September 9, 2026 to discuss the Complete Response Letter (CRL) issued on July 2, 2026...
OmniAb (NASDAQ: OABI) has announced a global collaboration and license agreement with Eli Lilly and Company (NYSE: LLY) for a new ion channel program, leveraging OmniAb’s technology platform and expertise in ion channel...
Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) has appointed Ryan Simms, PhD, as chief operating officer (COO) and head of radiopharmaceutical programs, strengthening the company’s leadership and...
Profound Medical (NASDAQ: PROF; TSX: PRN) has announced the introduction of its latest Treatment Delivery Console (TDC) software being deployed across Profound’s TULSA-PRO-installed base. According to Profound, the TDC...
Profound Medical (NASDAQ: PROF; TSX: PRN) has announced the launch of Let’s Huddle, a global patient community designed to empower men and their families with education, connection, and support throughout every...
Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that Intermountain Health, in the Mountain West region, has become the first health system in the U.S. to commercially deploy Perimeter’s...
Kamada (NASDAQ: KMDA; TASE: KMDA.TA) has announced that CFO Chaime Orlev will step down effective December 31, 2026, to pursue other opportunities and will provide transitional support to the incoming CFO. The company...
Valion Bio (NASDAQ: VBIO) has announced that the Armed Forces Radiobiology Research Institute (AFRRI), under its contract with the National Institute of Allergy and Infectious Diseases, is conducting a U.S. Department...
Clearmind Medical (NASDAQ: CMND; FSE: CWY0) has announced positive permeation study results from its ongoing intranasal MEAI development program. According to Clearmind, early-stage studies of its intranasal MEAI...